TREOS Bio Partners with Charit Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

Image for article TREOS Bio Partners with Charit Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
News Source : Financial Post

News Summary

  • Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer.
  • PolyPEPI1018 is TREOS Bio’s lead off-the-shelf multi-peptide active cancer immunotherapy designed to convert immunologically “cold” tumors to ‘hot’ tumors.
  • The therapy has demonstrated encouraging clinical activity across three Phase I/II trials (44 patients in total) in advanced MSS CRC.
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatm [+6053 chars]

Must read Articles